Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 1/20 | 0.41 |
| ▸ | GABRD | O14764 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14967024 | 0.91 | ALDH1A1 (0.44) | CYP3A4SMN1; SMN2TDP1ALDH1A1L3MBTL1 | |
| SCHEMBL3539265 | 0.87 | ALDH1A1 (0.51) | CYP3A4SMN1; SMN2TDP1ALDH1A1L3MBTL1 | |
| SCHEMBL22093090 | 0.86 | ALDH1A1 (0.43) | CYP3A4SMN1; SMN2TDP1ALDH1A1L3MBTL1 | |
| SCHEMBL25878362 | 0.84 | CYP3A4 (0.44) | CYP3A4SMN1; SMN2TDP1ALDH1A1L3MBTL1 | |
| SCHEMBL3542442 | 0.84 | CYP3A4 (0.44) | CYP3A4SMN1; SMN2TDP1ALDH1A1L3MBTL1 | |
| SCHEMBL25289588 | 0.82 | CYP2C9 (0.39) | SMN1; SMN2ALDH1A1HPGDMAPTKMT2A | |
| SCHEMBL30496249 | 0.82 | CYP2C9 (0.39) | SMN1; SMN2ALDH1A1HPGDMAPTKMT2A | |
| SCHEMBL22209075 | 0.82 | ALDH1A1 (0.50) | SMN1; SMN2ALDH1A1L3MBTL1HPGDMAPT | |
| SCHEMBL31697254 | 0.82 | ALDH1A1 (0.50) | SMN1; SMN2ALDH1A1L3MBTL1HPGDMAPT | |
| SCHEMBL3540275 | 0.82 | CYP3A4 (0.42) | CYP3A4SMN1; SMN2TDP1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250375432-A1 | COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2025-12-11 | — | — | US | disclosed |
| US-12404279-B2 | Deubiquitinase inhibitors and methods of use thereof | MOLECURE S.A. (PL) | 2025-09-02 | — | — | US | disclosed |
| US-12383540-B2 | Compounds that modulates AMPA receptor function | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2025-08-12 | — | — | US | disclosed |
| EP-4583867-A2 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | Latigo Biotherapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250154109-A1 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC | 2025-05-15 | — | — | US | disclosed |
| WO-2025029890-A1 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| EP-4472966-A2 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | Latigo Biotherapeutics, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| EP-4452984-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | Molecure S.A. (PL) | 2024-10-30 | — | — | EP | disclosed |
| US-20240336574-A1 | METHYL-SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. | 2024-10-10 | — | — | US | disclosed |
| WO-2024054622-A2 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| EP-1899294-A1 | THERAPEUTIC AGENTS | Merck Sharp & Dohme Limited (GB) | 2008-03-19 | — | — | EP | disclosed |
| EP-1893566-A1 | CYCLOHEXANESULFONYL DERIVATIVES AS GLYT1 INHIBITORS TO TREAT SCHIZOPHRENIA | MERCK SHARP & DOHME LTD. (GB) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006134341-A1 | THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006131711-A1 | CYCLOHEXANESULFONYL DERIVATIVES AS GLYT1 INHIBITORS TO TREAT SCHIZOPHRENIA | MERCK SHARP & DOHME LIMITED (GB) | 2006-12-14 | — | — | WO | disclosed |
| US-20060276655-A1 | Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2006-12-07 | — | — | US | disclosed |
| EP-1114030-B1 | PYRIDINE KETONES USEFUL AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2005-06-01 | — | — | EP | disclosed |
| US-6498125-B2 | Pyridine ketones useful as herbicides | SYNGENTA PARTICIPATIONS AG (CH) | 2002-12-24 | — | — | US | disclosed |
| US-20020016345-A1 | Pyridine ketones useful as herbicides | SYNGENTA PARTICIPATIONS AG (CH) | 2002-02-07 | — | — | US | disclosed |
| EP-1114030-A1 | PYRIDINE KETONES USEFUL AS HERBICIDES | Syngenta Participations AG (CH) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000015615-A1 | PYRIDINE KETONES USEFUL AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154109-A1 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | SCN8A, TRPV1, SCNN1A | CYP3A4 3430/4885SMN1; SMN2 741/4885TDP1 4311/4885 |
| US-20060276655-A1 | Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia | GLRA1, GNMT, MGAT1 | CYP3A4 1451/4885SMN1; SMN2 4074/4885TDP1 3651/4885 |
| US-20250375432-A1 | COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION | GRIN1, GRM1, GRIN2A | CYP3A4 1974/4885SMN1; SMN2 2592/4885TDP1 1642/4885 |
| US-12383540-B2 | Compounds that modulates AMPA receptor function | GRIN1, GRM1, GRIN2A | CYP3A4 2111/4885SMN1; SMN2 2277/4885TDP1 1779/4885 |
| US-20020016345-A1 | Pyridine ketones useful as herbicides | DDT, PDHA1, IDH2 | CYP3A4 158/4885SMN1; SMN2 3751/4885TDP1 2283/4885 |
| US-12404279-B2 | Deubiquitinase inhibitors and methods of use thereof | USP7, USP28, USP1 | CYP3A4 4130/4885SMN1; SMN2 2139/4885TDP1 876/4885 |
| US-20240336574-A1 | METHYL-SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | P2RX5, HRH4, TRPV1 | CYP3A4 396/4885SMN1; SMN2 2710/4885TDP1 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.